Literature DB >> 11141484

Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1.

V A Ploplis1, I Cornelissen, M J Sandoval-Cooper, L Weeks, F A Noria, F J Castellino.   

Abstract

Clinical studies have indicated that high plasma levels of fibrinogen, or decreased fibrinolytic potential, are conducive to an increased risk of cardiovascular disease. Other investigations have shown that insoluble fibrin promotes atherosclerotic lesion formation by affecting smooth muscle cell proliferation, collagen deposition, and cholesterol accumulation. To directly assess the physiological impact of an imbalanced fibrinolytic system on both early and late stages of this disease, mice deficient for plasminogen activator inhibitor-1 (PAI-1(-/-)) were used in a model of vascular injury/repair, and the resulting phenotype compared to that of wild-type (WT) mice. A copper-induced arterial injury was found to generate a lesion with characteristics similar to many of the clinical features of atherosclerosis. Fibrin deposition in the injured arterial wall at early (7 days) and late (21 days) times after copper cuff placement was prevalent in WT mice, but was greatly diminished in PAI-1(-/-) mice. A multilayered neointima with enhanced collagen deposition was evident at day 21 in WT mice. In contrast, only diffuse fibrin was identified in the adventitial compartments of arteries from PAI-1(-/-) mice, with no evidence of a neointima. Neovascularization was observed in the adventitia and was more extensive in WT arteries, relative to PAI-1(-/-) arteries. Additionally, enhanced PAI-1 expression and fat deposition were seen only in the arterial walls of WT mice. The results of this study emphasize the involvement of the fibrinolytic system in vascular repair processes after injury and indicate that alterations in the fibrinolytic balance in the vessel wall have a profound effect on the development and progression of vascular lesion formation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11141484      PMCID: PMC1850258          DOI: 10.1016/S0002-9440(10)63949-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

1.  Smooth muscle cell outgrowth stimulated by fibrin degradation products. The potential role of fibrin fragment E in restenosis and atherogenesis.

Authors:  M Naito; C M Stirk; E B Smith; W D Thompson
Journal:  Thromb Res       Date:  2000-04-15       Impact factor: 3.944

Review 2.  Regulation of vascular homeostasis by nitric oxide.

Authors:  M W Radomski; S Moncada
Journal:  Thromb Haemost       Date:  1993-07-01       Impact factor: 5.249

3.  Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study.

Authors:  T W Meade; V Ruddock; Y Stirling; R Chakrabarti; G J Miller
Journal:  Lancet       Date:  1993-10-30       Impact factor: 79.321

Review 4.  Animal models in atherosclerosis research.

Authors:  M P Jokinen; T B Clarkson; R W Prichard
Journal:  Exp Mol Pathol       Date:  1985-02       Impact factor: 3.362

5.  Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1.

Authors:  H Sjöland; D T Eitzman; D Gordon; R Westrick; E G Nabel; D Ginsburg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-03       Impact factor: 8.311

6.  Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor.

Authors:  G Ambrosio; A Oriente; C Napoli; G Palumbo; P Chiariello; G Marone; M Condorelli; M Chiariello; M Triggiani
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

7.  Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells.

Authors:  P G Tipping; P Davenport; M Gallicchio; E L Filonzi; J Apostolopoulos; J Wojta
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

8.  Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.

Authors:  P Carmeliet; L Kieckens; L Schoonjans; B Ream; A van Nuffelen; G Prendergast; M Cole; R Bronson; D Collen; R C Mulligan
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

9.  Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes.

Authors:  J A Hamilton; G A Whitty; H Stanton; J Wojta; M Gallichio; K McGrath; G Ianches
Journal:  Blood       Date:  1993-12-15       Impact factor: 22.113

10.  Regulation of plasminogen activator inhibitor-1 levels in human monocytes.

Authors:  J A Hamilton; G A Whitty; J Wojta; M Gallichio; K McGrath; G Ianches
Journal:  Cell Immunol       Date:  1993-11       Impact factor: 4.868

View more
  14 in total

1.  Multifaceted role of plasminogen activator inhibitor-1 in regulating early remodeling of vein bypass grafts.

Authors:  Yan Ji; Tammy L Strawn; Elizabeth A Grunz; Meredith J Stevenson; Alexander W Lohman; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-05-12       Impact factor: 8.311

Review 2.  Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.

Authors:  Victoria A Ploplis
Journal:  Curr Drug Targets       Date:  2011-11       Impact factor: 3.465

3.  Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice.

Authors:  J C Chan; D A Duszczyszyn; F J Castellino; V A Ploplis
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

4.  The effects of the overexpression of recombinant uncoupling protein 2 on proliferation, migration and plasminogen activator inhibitor 1 expression in human vascular smooth muscle cells.

Authors:  J-Y Park; K-G Park; H-J Kim; H-G Kang; J D Ahn; H-S Kim; Y M Kim; S M Son; I J Kim; Y K Kim; C D Kim; K-U Lee; I-K Lee
Journal:  Diabetologia       Date:  2005-04-13       Impact factor: 10.122

5.  Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices.

Authors:  N Garg; N Goyal; T L Strawn; J Wu; K M Mann; D A Lawrence; W P Fay
Journal:  J Thromb Haemost       Date:  2010-05-12       Impact factor: 5.824

6.  Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia.

Authors:  Jianbo Wu; Lin Peng; Grainne A McMahon; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-02       Impact factor: 8.311

7.  Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation.

Authors:  Yan Ji; Zhen Weng; Philip Fish; Neha Goyal; Mao Luo; Samantha P Myears; Tammy L Strawn; Bysani Chandrasekar; Jianbo Wu; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-09-22       Impact factor: 8.311

Review 8.  Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.

Authors:  Rohan Samarakoon; Paul J Higgins
Journal:  Thromb Haemost       Date:  2008-12       Impact factor: 5.249

9.  Severe deficiency of coagulation Factor VII results in spontaneous cardiac fibrosis in mice.

Authors:  H Xu; F Noria; M J Sandoval-Cooper; H Menchen; D L Donahue; V A Ploplis; F J Castellino
Journal:  J Pathol       Date:  2009-02       Impact factor: 7.996

10.  Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.

Authors:  Tessa M Simone; Paul J Higgins
Journal:  Mol Med Ther       Date:  2012-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.